Socio Demographic Profile of Rifampicin Resistant Patient in Surat City
Keywords:
tuberculosis, rifampicin resistant tuberculosis, socio-demographic variablesAbstract
Introduction: Drug resistance tuberculosis poses a major hindrance in effective control of tuberculosis. This study aims to assess the relationship of certain socio-demographic factors and Rifampicin resistant tuberculosis.
Settings and Design: It was a case control study which included 33 cases and 66 controls who had been registered in Revised National Tuberculosis Control Programme (RNTCP) and tested for Rifampicin resistance using CBNAAT test .Patient having resistance to rifampicin identified by CBNAA Test were considered as cases whereas patient sensitive to rifampicin identified by CBNAA Test were considered to be controls
Method: The study was conducted by pretested semi-structured questionnaire. . Information was gathered from the patients by taking interview.
Results: Rifampicin resistant tuberculosis was more in male (51.5%) than female (48.5%). Maximum number of cases was observed in age group 20-40 years. 51.5 % of the cases were illiterate. 33.33% cases were unmarried whereas 66.7% were married. 84.8 of the cases were Hindus. 81.8% of the cases were non- migrants as compared to 59.1% controls .According to modified Prasad’s classification (AICPI index Surat (262) nov-2004) it was observed that maximum cases were from class IV and maximum controls were from class III.
Conclusions: Rifampicin resistance was higher among males and non- migrants significantly. Further explorations in these areas are required to effectively control the disease.
References
Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituber-culosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet (London, England). 2006 Dec; 368(9553):2142-2154..
American Thoracic society.1994.Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med.149:1359-1374
Mitchison , D.A 1998. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc.Lung Dis.2:10-15
Somoskovi, A., Parsons, L.M. and Salfinger, M. (2001) The Mo-lecular Basis of Resistance to Isoniazid, Rifampin, and Pyrazi-namide in Mycobacterium tuberculosis. Respiratory Research, 2, 164-168. http://dx.doi.org/10.1186/rr54
Felmlee T.A., Liu A.Q., Whelen C., et al. Genotypic detection of-Mycobacterium tuberculosis rifampicin resistance: comparison of single strand confirmation polymorphism and dideoxy fingerprinting. J. Clin. Microbiology. 1995;33:1617–1623
García de Viedma D, del Sol Díaz Infantes M, Lasala F, Chaves F, Alcalá L, Bouza E. New real-time PCR able to detect in a single tube multiple rifampin resistance mutations and high-level isoniazid resistance mutations in Mycobacterium tuberculosis. J Clin Microbiol. 2002;40(3):988-995. doi:10.1128/ JCM. 40.3. 988-995.2002
Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61(2):158-163. doi:10.1136/thx.2005.045963.
Lomtadze N, Aspindzelashvili R, Janjgava M, et al. Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. Int J Tuberc Lung Dis. 2009;13(1):68-73.
Ejaz, M., Siddiqui, A.R., Rafiq, Y., Malik, F.R., Channa, A.A., Mangi, R., Habib, F., & Hasan, R. (2010). Prevalence of multi-drug resistant tuberculosis in Karachi, Pakistan: identification of at risk groups. Transactions of the Royal Society of Tropical Medicine and Hygiene, 104 8, 511-7
Rifat M, Milton AH, Hall J, Oldmeadow C, Islam MA, Husain A, et al. (2014) Development of Multidrug Resistant Tuberculosis in Bangladesh: A Case-Control Study on Risk Factors. PLoS ONE 9(8): e105214. https://doi.org/10.1371/journal.pone. 0105214
Atre SR, D'Souza DT, Vira TS, Chatterjee A, Mistry NF. Risk factors associated with MDR-TB at the onset of therapy among new cases registered with the RNTCP in Mumbai, India. Indian J Public Health. 2011;55(1):14-21. doi:10.4103/0019-557X. 82536
Goswami A, Chakraborty U, Mahapatra T, Mahapatra S, Muk-herjee T, Das S, et al. (2014) Correlates of Treatment Out-comes and Drug Resistance among Pulmonary Tuberculosis Patients Attending Tertiary Care Hospitals of Kolkata, India. PLoS ONE 9(10): e109563. https://doi.org/10.1371/journal. pone.0109563
Hudelson P. Gender differentials in tuberculosis: the role of socio-economic and cultural factors. Tuber Lung Dis. 1996;77:391–400.
Gaude G.S., Hattiholli J., Kumar P. Risk factors and drug-resistance patterns among pulmonary tuberculosis patients in northern Karnataka region, India. Nigerian medical journal: Journal of the Nigeria Medical Association. 2014;55(4):327–332.
Vijay S, Kumar P, Chauhan LS, Vollepore BH, Kizhakkethil UP, Rao SG (2010) Risk Factors Associated with Default among New Smear Positive TB Patients Treated Under DOTS in India. PLoS ONE 5(4): e10043.
Chadha SL, Bhagi RP. Treatment outcome in tuberculosis pa-tients placed under directly observed treatment short course (DOTS): A cohort study. Indian J Tuberc. 2000;47:155–8.
Chen J, Qi L, Xia Z, Shen M, Shen X, Mei J, et al. (2013) Which Urban Migrants Default from Tuberculosis Treatment in Shanghai, China? PLoS ONE 8(11): e81351. https://doi.org/ 10.1371/journal.pone.0081351C
Kirwan D E, Nicholson BD, Baral SC, James NN (2009) The so-cial reality of migrant men with tuberculosis in Kathmandu: Implications for DOT in practice. Tropical Medicine & International Health 14(12):1442-7 DOI:10.1111/j.1365-3156.2009. 02405.x
Wei X, Chen J, Chen P, Newell JN, Li H, Sun C, Mei J, Walley JD., et al. Trop Med Int Health. 2009 Jul;14(7):754-60. doi: 10.1111/j.1365-3156.2009.02286.x. Epub 2009 Apr 17. Trop Med Int Health. 2009. PMID: 19392747
Caminero, J.A. (2010) Multidrug-Resistant Tuberculosis: Epi-demiology, Risk Factors and Case Finding. International Jour-nal of Tuberculosis and Lung Disease, 14, 382-390.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.
